# Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

> **NCT07020065** · PHASE2 · RECRUITING · sponsor: **Swiss Cancer Institute** · enrollment: 156 (estimated)

## Conditions studied

- Metastatic NSCLC - Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Cemiplimab
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed & Gemcitabine
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT07020065
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-10
- **Primary completion:** 2028-09
- **Final completion:** 2030-09
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07020065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07020065, "Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07020065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*